Palisade Bio, Inc. Stock Analysis & AI Score
Palisade Bio, Inc. (PALI) has an ST Score of 66.7 (B), driven by its Financial Strength (A+) and held back by its Momentum (D+). Analysts rate it Buy with a $4.50 price target (+186.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Palisade Bio, Inc. (PALI) has an ST Score of 66.7 (B), driven by its Financial Strength (A+) and held back by its Momentum (D+). Analysts rate it Buy with a $4.50 price target (+186.6% upside).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumD+
All factor grades
- Financial StrengthA+
- SentimentA+
- ForecastA
- ProfitabilityB+
- GrowthB
- ValuationB-
- MomentumD+
- Piotroski4/9
Contact
PALI stock: frequently asked questions
What is PALI's ST Score?
Palisade Bio, Inc. (PALI) has an ST Score of 66.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PALI a buy, hold, or sell?
Analysts rate PALI a Buy, with a price target of $4.50 (+186.6% vs the current price). Our ST Score grades it B (66.7/100). The ST Score is a data-driven signal, not a recommendation.
What are PALI's factor grades?
Valuation B-, Profitability B+, Financial Strength A+, Momentum D+, Growth B, Forecast A, Sentiment A+.
What is PALI's valuation grade?
Palisade Bio, Inc. (PALI) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PALI's growth grade?
Palisade Bio, Inc. (PALI) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PALI's profitability grade?
Palisade Bio, Inc. (PALI) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PALI's financial strength grade?
Palisade Bio, Inc. (PALI) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PALI?
The average analyst price target for Palisade Bio, Inc. (PALI) is $4.50 from 4 analysts, which is +186.6% versus the recent price of $1.57.
What is PALI's Piotroski score?
Palisade Bio, Inc. (PALI) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.